Introducing Omanta (YC S26) the personalized research lab for each patient. Omanta integrates a patient's full medical record, personal genomics, and the latest scientific evidence to understand the molecular drivers of their disease. It maps existing and emerging therapies against their biology. And when the right treatment doesn't exist yet, it launches a personalized campaign to build it. Even the hardest cases rarely have a team dedicated to solving them. Physicians make high-stakes calls with limited time, while data and therapies emerge every week. Science moves fast, but reaching the patient can take years. That's the gap Omanta was built to close. Founders Alfredo Gonzalez, PhD and Ranad Humeidi, PhD spent years on some of the most difficult cancer cases. Alfredo led the personalized therapeutic campaign behind Sid Sijbrandij's complete remission. Together they've worked with leading institutions on personalized vaccines, CAR-T, drug repurposing, expanded access, and continuous molecular monitoring. They've seen what becomes possible when the full force of modern science is organized around one person. They met eight years ago doing early CRISPR cancer research at the Broad Institute of MIT and Harvard. Alfredo Gonzalez (CEO) has a PhD in bioinformatics from UCLA and led research projects across the Broad Institute, UCLA, and Harvard. Ranad Humeidi (CSO) has a PhD in chemical biology from Harvard, and has built and run rare-cancer programs for individual patients when standard options ran out. omanta.com A research lab, for one. Linked-in: bit.ly/omanta-linkedin YC Launch: bit.ly/omanta-yc